While the resveratrol effects are intensively studied in animal models only few clinical trials were conducted so far to study the effects of resveratrol supplementation in the context of human obesity and coronary artery disease (Timmers et al., 2011; Tome-Carneiro et al., 2013b), yet there exists some controversy (Poulsen et al., 2013) and the effect of resveratrol on the expression of inflammatory cytokines, in particular IL-6, IL-8, and MCP-1 in obesity remains to be further investigated. Here, CXCL8 is linked to obesity due to melanocortin 4 receptor deficiency.